Market Place
Sourcing Support
Atai Life Sciences Reports Q3 2024 Results & Corporate News
13 Nov 2024 //
GLOBENEWSWIRE
atai Life Sciences to Participate in the 2024 Maxim Healthcare Summit
15 Oct 2024 //
GLOBENEWSWIRE
IntelGenx Court Approves Sale Proposal from atai Life Sciences AG
02 Oct 2024 //
GLOBENEWSWIRE
Atai Life Sciences To Join H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Atai Reports Positive Results From Phase 1b Trial Of VLS-01
13 Aug 2024 //
GLOBENEWSWIRE
Atai Life Sciences Reports Q2 2024 Results And Corporate Updates
13 Aug 2024 //
GLOBENEWSWIRE
Atai Life Sciences To Participate In Canaccord Genuity Growth Conference
07 Aug 2024 //
GLOBENEWSWIRE
Atai Life Sciences To Participate In Neuro Perspectives
26 Jun 2024 //
GLOBENEWSWIRE
Atai Life Sciences Updates On Beckley Psytech`s ELE-101 Trial For Depression
20 Jun 2024 //
GLOBENEWSWIRE
atai At Jefferies Global Healthcare Conference 2024
31 May 2024 //
GLOBENEWSWIRE
Atai Board Strengthened: Independent Director Appointments Announced
23 May 2024 //
GLOBENEWSWIRE
atai Life Sciences Reports Q1 2024 Financials, Corporate Updates
15 May 2024 //
GLOBENEWSWIRE
atai Doses First BPL-003 Patient in Depression Study Part 2
24 Apr 2024 //
GLOBENEWSWIRE
atai`s Beckley Psytech Phase 1 Study Published
17 Apr 2024 //
GLOBENEWSWIRE
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
atai Announces Positive Results from Beckley Phase 2a of BPL-003 in Depression
27 Mar 2024 //
GLOBENEWSWIRE
IntelGenx Enters Into a Third Amended Agreement atai Life Sciences
11 Mar 2024 //
PRESS RELEASE
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
04 Mar 2024 //
GLOBENEWSWIRE
atai Life Sciences to Participate in TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
06 Feb 2024 //
GLOBENEWSWIRE
Atai Life Sciences Announces Strategic Investment in Beckley Psytech
04 Jan 2024 //
GLOBENEWSWIRE
atai Life Announces Positive Results from Single Dose Phase 1 Study with EMP-01
02 Jan 2024 //
GLOBENEWSWIRE
IntelGenx Announces Closing of Subsequent Non-Brokered Private Placement
05 Dec 2023 //
GLOBENEWSWIRE
atai Life Sciences Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Atai Life to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
06 Oct 2023 //
GLOBENEWSWIRE
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01
02 Oct 2023 //
GLOBENEWSWIRE
atai Life Sciences to Participate in the 2023 Healthcare Conference
14 Sep 2023 //
GLOBENEWSWIRE
atai Life Sciences to Participate in Upcoming September Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Atai Life Sciences Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
atai Life Announces Results from Phase 1 IV-to-Subcutaneous Study of PCN-101
08 Aug 2023 //
GLOBENEWSWIRE
atai Life Sciences to Participate in Upcoming June Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
atai Life Sciences Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
atai Life Sciences to Participate in Upcoming May Investor Conference
02 May 2023 //
GLOBENEWSWIRE
atai Life Sciences Announces First Subject Dosed in the Phase 1 Study of PCN-101
13 Apr 2023 //
GLOBENEWSWIRE
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
06 Mar 2023 //
GLOBENEWSWIRE
2 months after depression fail, Atai lays off 30% of staff
06 Mar 2023 //
FIERCE BIOTECH
atai Life Sciences to Participate the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
GABA Therapeutics Announces Positive Results from Phase 1 Trial of GRX-917
09 Jan 2023 //
GLOBENEWSWIRE
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine)
06 Jan 2023 //
GLOBENEWSWIRE
atai Life Sciences announces results from Kures ` Phase 1 study of KUR-101
25 Dec 2022 //
GLOBENEWSWIRE
atai Life Sciences Announces Results from the Kures Ph1 Trial of KUR-101
23 Dec 2022 //
GLOBENEWSWIRE
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007
19 Dec 2022 //
GLOBENEWSWIRE
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort
16 Dec 2022 //
GLOBENEWSWIRE
atai Life Sciences Appoints Dr. Sahil V. Kirpekar as Chief Business Officer
29 Nov 2022 //
GLOBENEWSWIRE
Acquisition of Shares in Atai Life Sciences and Compass Pathways
24 Nov 2022 //
FIRSTWORDPHARMA
atai Life Sciences &Massachusetts Announce Initiation of Clinical Study
17 Nov 2022 //
GLOBENEWSWIRE
atai Life Sciences Reports 3Q 2022 Financial Results and Business Update
10 Nov 2022 //
GLOBENEWSWIRE
atai Life Sciences to Announce 3Q 2022 FYR and Business Update
01 Nov 2022 //
GLOBENEWSWIRE
atai Life Sciences to Participate in November Investor Events & Conferences
01 Nov 2022 //
GLOBENEWSWIRE
atai , Perception Neurosci, Completes Enrollment for Phase 2a Trial of PCN-101
25 Oct 2022 //
GLOBENEWSWIRE
atai Life Sciences Announces R&D Day Agenda
20 Oct 2022 //
GLOBENEWSWIRE
atai to Initiate PhI Trial for Sol-gel Based Direct-to-Brain Drug Delivery Tech
18 Oct 2022 //
GLOBENEWSWIRE
IntelGenx’s Collaboration with atai Life Sciences Culminates For Clinical Study
13 Oct 2022 //
GLOBENEWSWIRE
atai Life Sciences Announces Positive Initial Results for Pha1 Trial of KUR-101
12 Oct 2022 //
GLOBENEWSWIRE
Atai achieves positive results in phase 1 trial of kratom-derived drug
12 Oct 2022 //
SEEKING ALPHA
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial
05 Oct 2022 //
GLOBENEWSWIRE
atai Life Sciences to Participate in Oct Investor Events & Host Virtual R&D Day
04 Oct 2022 //
GLOBENEWSWIRE
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA EMP-01
27 Sep 2022 //
GLOBENEWSWIRE
Atai drops pipeline assets, takes on debt to extend cash runway
16 Aug 2022 //
FIERCEBIOTECH
